NKTX today
$1.34-$0.14 (-9.12%)close Nov 12, 2026Trend
DailyDowntrend (confirmed)
4 hourStrong Bearish
1 hourStrong Bearish
15 minStrong Bearish
5 minStrong Bearish
Daily trend turns up above $3.30
Key levels
Resistance$1.66
Resistance$1.42
Latest news & SEC filings
ProductNkarta reports favorable safety data for NKX019 in Ntrust study
ProductNkarta says its cell-based treatment showed no safety issues in five autoimmune diseases
ProductNkarta shares pooled safety data for NKX019 across 40 Ntrust trial participants
AnalystNeedham keeps Buy rating on Nkarta with $11 price target
All NKTX news →About Nkarta
Nkarta is a clinical-stage biopharmaceutical company that develops cell therapies using natural killer cells from healthy donors, designed to be stored and ready for use without matching to a specific patient. Its main candidate, NKX019, is a CAR NK therapy that targets CD19 and is being tested in autoimmune conditions including lupus nephritis, primary membranous nephropathy, systemic sclerosis, myositis, and ANCA-associated vasculitis. An earlier program, NKX101, was studied in blood cancers but is no longer the primary focus. The company makes its clinical supplies at its own facilities in South San Francisco, California.
Based on the company's 10-K filed Mar 25, 2026.
Nasdaq · Healthcare
Nkarta, Inc. (NKTX)
What Is the Price Target for NKTX?
SEPT Low Target
$10.00
SEPT Mid Target
$11.00
SEPT High Target
$12.00
Analyst Consensus
$11.00
Is NKTX a Buy or Sell Right Now?
Thesis
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for NKTX.
Start Free Trial →Is NKTX Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
P/B, Analyst Consensus
Fair Value
$10.12
12
Moat Score
NONE
1/9
Piotroski Score
-1.6
Altman Z-Score
What Is Smart Money Doing with NKTX?
Insider Signal
NEUTRAL
0 buys / 2 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
MEDIUM
Signal: NEUTRAL
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →NKTX Growth Story
Revenue YoY
N/A%
3yr Revenue CAGR
N/A%
EPS Growth YoY
11.88%
FCF Growth YoY
13.6%
Revenue Trend
UNKNOWN
Dark Pool Trades for NKTX
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for NKTX, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 18:30:09 | $1.34 | 1,521 | $$2K | SELL |
| 18:26:09 | $1.35 | 1,500 | $$2K | BUY |
| 18:05:28 | $1.35 | 4,000 | $$5K | BUY |
| 17:53:54 | $1.35 | 5,000 | $$7K | BUY |
| 17:45:16 | $1.35 | 3,000 | $$4K | BUY |
5 dark pool trades shown · $$20K preview volume
Real-time institutional flow, block trades, and net positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for Nkarta, Inc. (NKTX) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (4 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →NKTX — frequently asked questions
What is NKTX stock price today?
Nkarta, Inc. (NKTX) is at $1.34, down 9.12% (-$0.14) at the Nov 12, 2026 close.
Why is NKTX stock moving today?
Latest NKTX news — Nov 12, 2026: Nkarta reports favorable safety data for NKX019 in Ntrust study · Nov 11, 2026: Nkarta says its cell-based treatment showed no safety issues in five autoimmune diseases
What is the NKTX price target?
The average analyst price target for NKTX is $11.00, ranging from $10 to $12, based on 4 analysts.
What do analysts rate NKTX?
Analyst ratings for NKTX: 0 Buy, 6 Hold, 0 Sell — consensus Hold.
Did NKTX beat earnings?
NKTX last reported on Nov 5, 2026: EPS -$0.45 vs -$0.42 expected — a miss of 7.1%.
Does NKTX pay a dividend?
NKTX does not currently pay a dividend.
What are NKTX support and resistance levels?
Resistance: $1.42, $1.66, $1.88.
What are insiders doing with NKTX?
Insider activity: NEUTRAL, 0 buys and 2 sells in the last 90 days.
What is the latest news on NKTX?
Nov 12, 2026: Nkarta reports favorable safety data for NKX019 in Ntrust study · Nov 11, 2026: Nkarta says its cell-based treatment showed no safety issues in five autoimmune diseases · Nov 11, 2026: Nkarta shares pooled safety data for NKX019 across 40 Ntrust trial participants